Ovarian Cancer
Conditions
Keywords
Ovarian cancer；Platinum-resistant；chemosensitivity
Brief summary
The research purpose of this study is to use organoid cultured from patients' own ovarian cancer tissues as models, screen potential clinical therapeutic drugs (such as paclitaxel, gemcitabine, etc.) in vitro, formulate individualized drug treatment plans for individual patient, and evaluate the clinical application value of organ like drug sensitivity technology.
Detailed description
Under the guidance of ultrasound, the lesions were punctured to obtain tumor cells; The cells were amplified and cultured by organ like culture method to establish ovarian cancer like organoid. The drug sensitivity tests of different drugs were carried out on similar organs. Number of drugs tested: 10 (paclitaxel, carboplatin, lobaplatin, doxorubicin, etc.); After the test is completed, sufficient chemotherapy for full course of treatment shall be carried out according to the drug sensitivity results; After chemotherapy, blood and imaging evaluation were performed; Collect the information of patients from initial treatment to the end of chemotherapy; Matching the corresponding number of patients with platinum resistant relapse who did not undergo organ like culture; At each end point, the evaluation and comparison were carried out and the research conclusions were drawn.
Interventions
DEVICEOrganoid culture
Tumor like organ is a kind of organ cultured from tissues of tumor patients, which is a small tumor growing in a culture dish. Compared with the traditional two-dimensional culture system, the most important feature of this technological innovation is that it can directly use the patient's own tissue to culture organ like cells. At the same time, these organ like cells can well replicate some key characteristics of the primary tumor and retain the pathological form and biological mechanism of the patient's tissue
Sponsors
The First Affiliated Hospital of Xiamen University
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
20 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
1. Patients diagnosed as primary nonmucous epithelial ovarian cancer with stage III or above by previous pathological diagnosis; 2. According to the relevant standards formulated by the World Health Organization (WHO) in 2014, measurable or assessable lesions are determined; 3. platinum-resistant epithelial ovarian cancer that has received more than 2 lines of chemotherapy; 4. There is no serious disease of important organs, and the patient can tolerate chemotherapy. Karnofsky score more than 60, and the expected survival period is more than half a year; 5. The liver, kidney and bone marrow functions were good.
Exclusion criteria
1. Patients with other malignant tumors; 2. Patients with nervous system diseases; 3. Hepatitis B virus and human papilloma virus infection; 4. Immune function defect or serious infection; 5. Patients who cannot communicate effectively, disagree with the research requirements, and do not understand the research purpose.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Objective remission rate | 6 months | partial or complete remission ratio according to RECIST criteria |
Secondary
| Measure | Time frame |
|---|---|
| Progression free survival | 3 years |
Countries
China
Contacts
Primary ContactJianFa Lan, Doctor
Outcome results
None listed